Filings
| Filing | Date | Type | Filed with |
|---|
| Prescient receives $3.4 million R&D Tax Refund | Nov 11, 2026 | Financing | ASX |
|---|
| Notification of cessation of securities - PTX | Nov 8, 2026 | Financing | ASX |
|---|
| Change of Company Secretary | Oct 22, 2026 | Management or board change | ASX |
|---|
| Results of Annual General Meeting | Oct 14, 2026 | Meeting outcome | ASX |
|---|
| Chair Address and CEO AGM Presentation | Oct 13, 2026 | Meeting outcome | ASX |
|---|
| September 2026 Quarterly Update and Appendix 4C | Oct 12, 2026 | Quarterly report | ASX |
|---|
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice | Oct 5, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - PTX | Sep 29, 2026 | Other filings | ASX |
|---|
| Section 708A Cleansing Notice | Sep 29, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - PTX | Sep 29, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - PTX | Sep 29, 2026 | Financing | ASX |
|---|
| PTX Successfully Completes $6m Raise Via SPP and Placement | Sep 22, 2026 | Financing | ASX |
|---|
| Proposed issue of securities - PTX | Sep 22, 2026 | Financing | ASX |
|---|
| Trading Halt | Sep 20, 2026 | Trading halt or suspension | ASX |
|---|
| Update - Proposed issue of securities - PTX | Sep 14, 2026 | Financing | ASX |
|---|
| Prescient Therapeutics - Extension of Share Purchase Plan | Sep 14, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Sep 13, 2026 | Meeting notice | ASX |
|---|
| Update - Proposed issue of securities - PTX | Sep 7, 2026 | Financing | ASX |
|---|
| Prescient Therapeutics - Extension of Share Purchase Plan | Sep 7, 2026 | Financing | ASX |
|---|
| PTX-100 CTCL Phase 2a study reaches review milestone | Sep 2, 2026 | Other filings | ASX |
|---|
| Prescient Share Purchase Plan Investor Presentation | Aug 25, 2026 | Financing | ASX |
|---|
| Prescient Therapeutics Opens SPP to Raise $7m Today | Aug 25, 2026 | Financing | ASX |
|---|
| Share Purchase Plan Cleansing Notice | Aug 25, 2026 | Financing | ASX |
|---|
| Proposed issue of securities - PTX | Aug 25, 2026 | Financing | ASX |
|---|
| Prescient Therapeutics Launches Share Purchase Plan for $7m | Aug 24, 2026 | Financing | ASX |
|---|
| Appendix 4E and 2026 Annual Report | Aug 20, 2026 | Annual report | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Aug 20, 2026 | Other filings | ASX |
|---|
| June 2026 Quarterly Update and Appendix 4C | Jul 26, 2026 | Quarterly report | ASX |
|---|
| March 2026 Quarterly Update and Appendix 4C | Apr 29, 2026 | Quarterly report | ASX |
|---|
| Appendix 4D and Half Year Financial Report | Feb 24, 2026 | Interim report | ASX |
|---|
| December 2025 Quarterly Update and Appendix 4C | Jan 29, 2026 | Quarterly report | ASX |
|---|
| PTX secures EU Authorisation to commence PTX-100 Trial | Dec 14, 2025 | Other filings | ASX |
|---|
| PTX secures EU Orphan Drug Designation for PTX-100 in CTCL | Nov 18, 2025 | Other filings | ASX |
|---|
| September Quarterly Updated and Appendix 4C | Oct 9, 2025 | Quarterly report | ASX |
|---|
| Appendix 4E and 2025 Annual Report | Aug 20, 2025 | Annual report | ASX |
|---|
| Prescient successfully completes $3 million Placement | Jul 31, 2025 | Financing | ASX |
|---|
| June 2025 Quarterly Update and Appendix 4C | Jul 30, 2025 | Quarterly report | ASX |
|---|
| Prescient announces results of SPP & Launches Placement | Jul 29, 2025 | Results | ASX |
|---|
| Trading Halt | Jul 28, 2025 | Trading halt or suspension | ASX |
|---|
| Prescient Therapeutics - Extension of Share Purchase Plan | Jul 22, 2025 | Financing | ASX |
|---|
| PTX Opens First U.S. Site for PTX-100 Phase 2a Trial | Jul 15, 2025 | Operations update | ASX |
|---|
| Prescient Therapeutics Extends Share Purchase Plan | Jul 14, 2025 | Financing | ASX |
|---|
| Prescient Therapeutics Opens Share Purchase Plan | Jul 1, 2025 | Financing | ASX |
|---|
| Prescient Therapeutics Launches Share Purchase Plan for $7m | Jun 30, 2025 | Financing | ASX |
|---|
| First Patient dosed for PTX-100 Phase 2a Study | May 26, 2025 | Other filings | ASX |
|---|
| March 2025 Quarterly Update and Appendix 4C | Apr 28, 2025 | Quarterly report | ASX |
|---|
| PTX-100 receives U.S. FDA Fast Track Designation | Apr 15, 2025 | Other filings | ASX |
|---|
| PTX Opens First Clinical site for PTX-100 Phase 2a Study | Mar 25, 2025 | Other filings | ASX |
|---|
| December 2024 Quarterly Update and Appendix 4C - amended | Jan 31, 2025 | Quarterly report | ASX |
|---|
| December 2024 Quarterly Update and Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| US FDA allows PTX-100 Ph2 trial | Dec 22, 2024 | Other filings | ASX |
|---|
| Appointment of Chief Executive Officer | Dec 17, 2024 | Management or board change | ASX |
|---|
| September 2024 Quarterly Update and Appendix 4C | Oct 30, 2024 | Quarterly report | ASX |
|---|
| Prescient CEO to step down in early 2025 | Sep 11, 2024 | Management or board change | ASX |
|---|
| Appendix 4E and 2024 Annual Report | Aug 26, 2024 | Annual report | ASX |
|---|
| June 2024 Quarterly Update and Appendix 4C | Jul 31, 2024 | Quarterly report | ASX |
|---|
| March 2024 Quarterly Update and Appendix 4C | Apr 30, 2024 | Quarterly report | ASX |
|---|
| December 2023 Quarterly Update and Appendix 4C | Jan 31, 2024 | Quarterly report | ASX |
|---|
| PTX-100 Ph1b results show excellent safety & efficacy in TCL | Dec 10, 2023 | Results | ASX |
|---|
| September 2023 Quarterly Update and Appendix 4C | Oct 30, 2023 | Quarterly report | ASX |
|---|
| Appendix 4E and 2023 Annual Report | Aug 24, 2023 | Annual report | ASX |
|---|
| June 2023 Quarterly Update and Appendix 4C | Jul 26, 2023 | Quarterly report | ASX |
|---|
| March 2023 Quarterly Update and Appendix 4C | Apr 27, 2023 | Quarterly report | ASX |
|---|
| Continued promising results in PTX-100 TCL trial | Mar 15, 2023 | Other filings | ASX |
|---|
| FDA grants broader orphan drug status to PTX100 for TCLs | Mar 8, 2023 | Other filings | ASX |
|---|
| December 2022 Quarterly Update and Appendix 4C | Jan 25, 2023 | Quarterly report | ASX |
|---|
| AGM Presentation | Nov 29, 2022 | Other filings | ASX |
|---|
| September 2022 Quarterly Update and Appendix 4C | Oct 30, 2022 | Quarterly report | ASX |
|---|
| PTX-100 Trial Update | Oct 24, 2022 | Other filings | ASX |
|---|
| Placement Results | Oct 10, 2022 | Financing | ASX |
|---|
| SPP Results and Placement | Oct 6, 2022 | Financing | ASX |
|---|
| PTX unveils CellPryme-A to boost CAR-T performance | Sep 22, 2022 | Other filings | ASX |
|---|
| PTX strategic collaboration with MD Anderson Cancer Center | Sep 6, 2022 | Other filings | ASX |
|---|
| Prescient Therapeutics Launches Share Purchase Plan | Aug 24, 2022 | Financing | ASX |
|---|
| Appendix 4E and 2022 Annual Report | Aug 23, 2022 | Annual report | ASX |
|---|
| PTX agreement with Thermo Fisher for scalable OmniCAR | Aug 17, 2022 | Other filings | ASX |
|---|
| PTX OmniCAR cell manufacturing contract for clinical trials | Aug 15, 2022 | Other filings | ASX |
|---|
| June 2022 Quarterly Update and Appendix 4C | Jul 24, 2022 | Quarterly report | ASX |
|---|
| US FDA Grants Orphan Drug Designation to PTX-100 for PTCL | Jul 14, 2022 | Other filings | ASX |
|---|
| Key OmniCAR Patent Granted in US | Jul 4, 2022 | Other filings | ASX |
|---|
| PTX CellPryme-M presentation | Jun 7, 2022 | Other filings | ASX |
|---|
| PTX unveils new clinic-ready CAR-T enhancement platform | Jun 7, 2022 | Other filings | ASX |
|---|
| PTX-200 AML expansion after another complete response | May 9, 2022 | Other filings | ASX |
|---|
| March 2022 Quarterly Update and Appendix 4C | Apr 28, 2022 | Quarterly report | ASX |
|---|
| Recruitment Open for Expansion Cohort of Phase 1B Study | Apr 5, 2022 | Other filings | ASX |
|---|
| December 2021 Quarterly Update and Appendix 4C | Jan 30, 2022 | Quarterly report | ASX |
|---|
| September 2021 Quarterly Activities and Appendix 4C | Oct 27, 2021 | Quarterly report | ASX |
|---|
| Investor Presentation - October 2021 | Oct 12, 2021 | Other filings | ASX |
|---|
| PTX data demonstrates key OmniCAR features in next gen CAR-T | Oct 12, 2021 | Other filings | ASX |
|---|
| Appendix 4E and 2021 Annual Report | Aug 30, 2021 | Annual report | ASX |
|---|
| June 2021 Quarterly Activities and Appendix 4C | Jul 29, 2021 | Quarterly report | ASX |
|---|
| PTX-100 trial advances following successful Phase 1b | Jul 26, 2021 | Other filings | ASX |
|---|
| PTX successful immunogenicity testing of OmniCAR | Jul 4, 2021 | Other filings | ASX |
|---|
| PTX Completes CAR-T Manufacturing Milestone for OmniCAR | Jun 23, 2021 | Other filings | ASX |
|---|
| Response to ASX Price Query | Jun 3, 2021 | Explanation request | ASX |
|---|
| PTX signs CAR-T agreement with Peter MacCallum | May 10, 2021 | Other filings | ASX |
|---|
| March 2021 Quarterly Update and Appendix 4C | Apr 29, 2021 | Quarterly report | ASX |
|---|
| PTX-200 AML Trial Progresses to Higher Dose | Apr 22, 2021 | Other filings | ASX |
|---|
| December 2020 Quarterly Update and Appendix 4C | Jan 27, 2021 | Quarterly report | ASX |
|---|
| PTX announces 3 next-gen CAR-T programs with OmniCAR | Jan 17, 2021 | Other filings | ASX |
|---|
| Prescient Receives $1.03m R&D Tax Rebate | Nov 10, 2020 | Other filings | ASX |
|---|
| September 2020 Quarterly Update and Appendix 4C | Oct 19, 2020 | Quarterly report | ASX |
|---|
| Response to ASX Query | Sep 16, 2020 | Explanation request | ASX |
|---|
| PTX Raises $7 million via Strongly Supported Placement | Aug 25, 2020 | Financing | ASX |
|---|
| Appendix 4E and 2020 Annual Report | Aug 25, 2020 | Annual report | ASX |
|---|
| Successful SPP Closed Early | Aug 18, 2020 | Other filings | ASX |
|---|
| Extension of Share Purchase Plan | Aug 14, 2020 | Financing | ASX |
|---|
| PTX Announces Cell Therapy Collaboration with Peter Mac | Aug 13, 2020 | Other filings | ASX |
|---|
| PTX-100 progresses to next cohort in basket clinical study | Aug 11, 2020 | Other filings | ASX |
|---|
| PTX-200 AML Trial Progresses to Next Dose Level | Aug 3, 2020 | Other filings | ASX |
|---|
| June 2020 Quarterly Update and Appendix 4C | Jul 21, 2020 | Quarterly report | ASX |
|---|
| 2 PTX Assets Chosen in Doherty Institute COVID-19 Program | Jul 21, 2020 | Other filings | ASX |
|---|
| Trading Pause | Jul 20, 2020 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation | May 25, 2020 | Trading halt or suspension | ASX |
|---|
| PTX signs next-gen anti-cancer platform from Penn & Oxford | May 25, 2020 | Other filings | ASX |
|---|
| Voluntary Suspension | May 25, 2020 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | May 21, 2020 | Trading halt or suspension | ASX |
|---|
| PTX-100 progresses to new dose, adds new site | Apr 21, 2020 | Other filings | ASX |
|---|
| March 2020 Quarterly Update and Appendix 4C | Apr 15, 2020 | Quarterly report | ASX |
|---|
| December 2019 Appendix 4C - Quarterly | Jan 31, 2020 | Quarterly report | ASX |
|---|
| PTX-200 High Overall Response in Ph2a Breast Cancer trial | Dec 22, 2019 | Other filings | ASX |
|---|
| Encouraging data from PTX-200 ovarian cancer trial | Dec 11, 2019 | Other filings | ASX |
|---|
| Third complete response in PTX-200 AML Trial | Nov 26, 2019 | Other filings | ASX |
|---|
| PTX in new CAR-T collaboration | Nov 17, 2019 | Other filings | ASX |
|---|
| 1st patient dosed in trial for first in class drug PTX-100 | Nov 13, 2019 | Other filings | ASX |
|---|
| Receipt of R&D Tax Rebate | Nov 7, 2019 | Other filings | ASX |
|---|
| Prescient Ausbiotech Ras Presentation | Oct 30, 2019 | Other filings | ASX |
|---|
| September 2019 Appendix 4C - Quarterly | Oct 29, 2019 | Quarterly report | ASX |
|---|
| Appendix 4E and 2019 Annual Report | Aug 25, 2019 | Annual report | ASX |
|---|
| June 2019 Appendix 4C - Quarterly | Jul 23, 2019 | Quarterly report | ASX |
|---|
| PTX Initiates Phase 1b Clinical Trial for PTX-100 | Jul 10, 2019 | Other filings | ASX |
|---|
| Change to Exercise Price of Options | May 30, 2019 | Other filings | ASX |
|---|
| Canadian Patent Granted for PTX-200 | May 15, 2019 | Other filings | ASX |
|---|
| Entitlement Offer Results and Shortfall Notification | Apr 26, 2019 | Financing | ASX |
|---|
| March 2019 Appendix 4C - Quarterly | Apr 24, 2019 | Quarterly report | ASX |
|---|
| Despatch of Entitlement Offer Documents | Apr 3, 2019 | Financing | ASX |
|---|
| Prospectus | Mar 24, 2019 | Offer document | ASX |
|---|
| Capital Raising Presentation - March 2019 | Mar 24, 2019 | Financing | ASX |
|---|
| Prescient Completes Equity Raising to Raise $9.1 Million | Mar 24, 2019 | Other filings | ASX |
|---|
| December 2018 Appendix 4C - Quarterly | Jan 31, 2019 | Quarterly report | ASX |
|---|
| Interim Durability Analysis of PTX-200 Breast Cancer Study | Dec 9, 2018 | Other filings | ASX |
|---|
| September 2018 Appendix 4C - Quarterly | Oct 31, 2018 | Quarterly report | ASX |
|---|
| Pipeline Collaboration for Next Generation Formulations | Oct 16, 2018 | Other filings | ASX |
|---|
| Change of Registry Address: Automic P/L - Sydney Office | Sep 28, 2018 | Other filings | ASX |
|---|
| Improved manufacturing route for PTX-100 | Sep 2, 2018 | Other filings | ASX |
|---|
| Appendix 4E and 2018 Annual Report | Aug 31, 2018 | Annual report | ASX |
|---|
| PTX-200 AML Study Expanded | Aug 29, 2018 | Other filings | ASX |
|---|
| June 2018 Appendix 4C - Quarterly | Jul 31, 2018 | Quarterly report | ASX |
|---|
| US Patent Granted for PTX-200 for Ovarian Cancer Treatment | Jul 25, 2018 | Other filings | ASX |
|---|
| March 2018 Appendix 4C - Quarterly | Apr 23, 2018 | Quarterly report | ASX |
|---|
| Response to Aware Query | Apr 11, 2018 | Other filings | ASX |
|---|
| PTX-200 Phase 1b Breast Cancer Trial Results | Apr 9, 2018 | Other filings | ASX |
|---|
| March 2018 Investor Presentation | Mar 18, 2018 | Other filings | ASX |
|---|
| December 2017 Appendix 4C - Quarterly | Jan 31, 2018 | Quarterly report | ASX |
|---|
| Clinical Trial Updates | Jan 28, 2018 | Other filings | ASX |
|---|
| Clinical Hold Lifted on PTX-200 Breast Cancer Trial | Dec 10, 2017 | Other filings | ASX |
|---|
| PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer | Nov 5, 2017 | Other filings | ASX |
|---|
| September 2017 Appendix 4C - Quarterly | Oct 26, 2017 | Quarterly report | ASX |
|---|
| PTX-100 to Re-enter Trials in Hematology Niche | Oct 2, 2017 | Other filings | ASX |
|---|
| Prescient to resume AML trial | Sep 3, 2017 | Other filings | ASX |
|---|
| Appendix 4E and 2017 Annual Report | Aug 29, 2017 | Annual report | ASX |
|---|
| June 2017 Appendix 4C - Quarterly | Jul 25, 2017 | Quarterly report | ASX |
|---|
| Novel PTX-100 Cancer Approach Published in Nature | Jun 18, 2017 | Other filings | ASX |
|---|
| Clinical Trial Update | May 28, 2017 | Other filings | ASX |
|---|
| PTX Broker Presentation | May 16, 2017 | Other filings | ASX |
|---|
| European Patent Granted for PTX-200 | May 11, 2017 | Other filings | ASX |
|---|
| Kansas University Joins PTXs AML Trial | May 7, 2017 | Other filings | ASX |
|---|
| FDA Grants Orphan Drug Designation for PTX-200 in AML | Apr 30, 2017 | Other filings | ASX |
|---|
| March 2017 Appendix 4C - Quarterly | Apr 27, 2017 | Quarterly report | ASX |
|---|
| Successful Completion of Phase 1b Breast Cancer Trial | Apr 6, 2017 | Other filings | ASX |
|---|
| Three Additional US Patents Granted | Mar 15, 2017 | Other filings | ASX |
|---|
| First Cohort Successfully Completed in Phase 1b/2 AML Trial | Mar 7, 2017 | Other filings | ASX |
|---|
| December 2016 Appendix 4C - Quarterly | Jan 24, 2017 | Quarterly report | ASX |
|---|
| First Patient Dosed on Phase 1b/2 AML Trial | Dec 13, 2016 | Other filings | ASX |
|---|
| Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation | Dec 8, 2016 | Other filings | ASX |
|---|
| September 2016 Appendix 4C - Quarterly | Oct 28, 2016 | Quarterly report | ASX |
|---|
| First patient at Moffitt dosed in Phase 1b/2 breast trial | Sep 26, 2016 | Other filings | ASX |
|---|
| Appendix 4E and 2016 Annual Report | Aug 31, 2016 | Annual report | ASX |
|---|
| USPTO Grants Allowances for Two PTX-200 Patents | Aug 4, 2016 | Other filings | ASX |
|---|
| Change to exercise price of options | Jul 20, 2016 | Other filings | ASX |
|---|
| June 2016 Appendix 4C - Quarterly | Jul 19, 2016 | Quarterly report | ASX |
|---|
| Yale Joins PTXs Phase 1b/2 AML Clinical Trial | Jun 15, 2016 | Other filings | ASX |
|---|
| Replacement Entitlement Offer Prospectus | Jun 3, 2016 | Financing | ASX |
|---|
| Offer Document | May 18, 2016 | Offer document | ASX |
|---|
| PTX Secures $7.0M Capital Raising | May 17, 2016 | Financing | ASX |
|---|
| March 2016 Appendix 4C - Quarterly | Apr 21, 2016 | Quarterly report | ASX |
|---|
| Executive Management Change | Mar 30, 2016 | Other filings | ASX |
|---|
| Virax Rights Offer Documentation - 25 May 2011 | Mar 30, 2016 | Offer document | ASX |
|---|
| Appendix 4D (31 Dec 2010) - 25 February 2011 | Mar 30, 2016 | Interim report | ASX |
|---|
| Exclusive License with Transgene for Novel Skin Cancer Immun | Mar 30, 2016 | Other filings | ASX |
|---|
| Terms Sheet - Skin Cancer | Mar 30, 2016 | Other filings | ASX |
|---|
| Appendix 4E | Mar 30, 2016 | Results | ASX |
|---|
| VIR201 HIV Vaccine published in AIDS Journal | Mar 30, 2016 | Other filings | ASX |
|---|
| Update on VIR201 HIV Vaccine Clinical Trial | Mar 30, 2016 | Other filings | ASX |
|---|
| Dutchess Continuous Investment Agreement - 10 January 2012 | Mar 30, 2016 | Other filings | ASX |
|---|
| Suspension from Official Quotation - VHLG | Mar 30, 2016 | Trading halt or suspension | ASX |
|---|
| TG1042 Batch Manufacturing Completed - 26 July 2011 | Mar 30, 2016 | Other filings | ASX |
|---|
| Rights Offer - 19 July 2011 | Mar 30, 2016 | Other filings | ASX |
|---|
This page holds 200 of 249 filings.